What Fervex Treats: Main Uses and Benefits

This combination product is relevant in contexts marked by increased discomfort and tension associated with the treatment of the common cold, rhinitis, and flu-like states.

The medication is commonly used to help address symptom clusters that may become intense or disruptive, including fever and systemic pain, alongside the irritative nasal and ocular symptoms characteristic of these conditions. It helps address symptoms such as elevated body temperature, headache, body aches, clear nasal discharge, sneezing, and watery eyes.

“This preparation supports the patient during difficult episodes by easing distress and providing concurrent symptomatic relief across key domains.”

Applied in clinical settings where supportive symptom management is appropriate, the medication is commonly used to help with managing symptom intensity. This contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases.

---

Quick Fact: Symptom Management for Systemic Discomfort and Irritative Rhinitis	Symptom Type	Specific Manifestation
Systemic	Fever, headache, generalized body aches
Irritative	Runny nose, sneezing, watery eyes

Regulatory References

1. Pharmacy Board of Kenya

Fervex is generally intended for adults and adolescents aged 15 years and older for the symptomatic treatment of cold, rhinitis, and flu-like symptoms. Specific pediatric formulations exist for younger children, such as Fervex Kids (typically for ages 6 and up), but the standard adult formulation is strictly contraindicated for those under 15 years old.

Fervex is contraindicated and should not be used by individuals with certain pre-existing conditions, due to the presence of its active ingredients: paracetamol, pheniramine maleate, and ascorbic acid.

Contraindication Category	Specific Conditions
Severe Organ Impairment	Severe liver disease (hepatic insufficiency).
Allergy	Known hypersensitivity or allergy to paracetamol, pheniramine, ascorbic acid, or any other constituent of the product.
Eye Conditions	Certain forms of glaucoma, specifically closed-angle glaucoma.
Urinary Issues	Risk of urinary retention due to urethro-prostatic disorders, such as in cases of prostate enlargement (prostatic adenoma).
Metabolic Disorders	Rare hereditary conditions like fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency (for sucrose-containing formulas); or phenylketonuria (PKU) for sugar-free formulas containing aspartame.

Additionally, Fervex is generally not recommended for use during pregnancy and breastfeeding without consulting a healthcare professional.

Interactions with other medicines and products

The official regulatory documents classify several substance categories as having clinically significant interactions with Fervex, primarily due to the active components Acetaminophen and Pheniramine maleate.

Contraindicated and Prohibited Combinations: Co-administration with other paracetamol-containing products is prohibited to strictly avoid the risk of overdose and potential hepatotoxicity. Similarly, due to the presence of the antihistamine component, consumption of alcoholic beverages is not recommended and is restricted, as is the co-use of Monoamine Oxidase Inhibitors (MAOIs) or other sedating H1 antihistamines.

Pharmacodynamic and Exposure Interactions: The product has documented pharmacodynamic interactions resulting in additive central depression when co-administered with other sedative medications, including morphine derivatives, neuroleptics, barbiturates, benzodiazepines, and sedative antidepressants. Furthermore, the official label requires caution when taken with Vitamin K Antagonists (Oral Anticoagulants), particularly at high Acetaminophen doses for extended periods, due to the officially described risk of increased anticoagulant effect and hemorrhagic risk.

Timing and Population Constraints: Specific timing rules exist for certain substances: Colestyramine must not be administered within one hour to prevent reduced Acetaminophen absorption. Population-specific notes advise caution when co-administering with Flucloxacillin in patients with established Glutathione Deficiency Risk Factors (e.g., chronic alcoholism or severe malnutrition), due to an increased risk of high anion gap metabolic acidosis.

The regulatory profile defines these restrictions to prevent additive pharmacodynamic risks and manage altered drug exposure for co-administered medicines.

️ Mechanism of Action

The action of this combination product is defined by three distinct and complementary pharmacological mechanisms, each modulating core physiological pathways.

Acetaminophen exerts its effect via inhibition of Cyclooxygenase (COX) enzyme activity predominantly within the Central Nervous System (CNS). This activity suppresses prostaglandin ( PGE2) synthesis in the hypothalamus, initiating a cascade that results in the lowering of the body's thermoregulatory set-point and modulation of central nociceptive signaling. The physiological outcome is systemic heat dissipation (antipyresis) and altered pain signal transmission.

Pheniramine maleate is a competitive antagonist at the Histamine H1 receptors in both central and peripheral tissues. This receptor blockade modulates signaling that drives increased capillary permeability and glandular hypersecretion in the upper respiratory mucosa. The resultant physiological effect is altered microvascular permeability and glandular secretory dynamics in the airways.

Sodium Ascorbate functions as an essential cofactor and antioxidant, engaging mechanisms that participate in cellular redox homeostasis and facilitating certain enzymatic reactions under conditions of high demand.

Fervex granules for oral solution are indicated for the symptomatic treatment of colds, rhinitis, nasopharyngitis, and flu-like conditions in adults and adolescents aged 15 years and older. This medicine contains a combination of Paracetamol (an analgesic and antipyretic), Pheniramine maleate (an antihistamine), and Ascorbic acid (Vitamin C).

Administration and Dosage

The contents of the sachet must be dissolved completely in a glass of hot or cold water and taken orally. The maximum duration of treatment should not exceed five days.

Patient Group	Recommended Single Dose	Minimum Interval Between Doses	Maximum Daily Dose
Adults and Adolescents geq 15 years	1 sachet (500 mg Paracetamol, 25 mg Pheniramine maleate, 200 mg Ascorbic acid)	4 hours	3 sachets

Note: Due to the risk of drowsiness associated with Pheniramine maleate, it is often recommended to take the medicine in hot water in the evening.

Important Warnings

• Do not exceed the maximum daily dose and the total daily dose of Paracetamol must not exceed 4 grams (including Paracetamol from other sources). Overdose can cause severe liver damage.
• Avoid the consumption of alcoholic beverages or sedatives during treatment, as this may increase the risk of drowsiness and reduced vigilance.
• In cases of severe renal impairment (creatinine clearance < 10 mL/min), the minimum interval between doses must be increased to 8 hours.
• If symptoms do not improve after 5 days of treatment, or if fever persists for more than 3 days, consult a healthcare professional.

Research evidence / Overview of Studies for Fervex

---

Evidence for Symptomatic Relief of Common Cold and Flu-Like Illnesses

Fervex, which combines an analgesic (Acetaminophen), an antihistamine (Pheniramine maleate), and Vitamin C, was studied in research exploring multiple symptoms associated with the acute or disruptive episodes of common cold and flu-like syndromes. The research base includes short-term, randomized controlled trials (RCTs). These RCTs often follow a double-blind, placebo-controlled design, which is the standard structure used in research exploring how symptoms change over time.

These studies explored outcomes related to physical discomfort and systemic imbalance, such as fever and headache, alongside outcomes linked to inflammatory or irritative states, like runny nose and sneezing. Research examined changes in the Total Symptom Score (TSS), which is a combined measure that allows researchers to look at the overall pattern of reported discomfort rather than just one symptom in isolation.

Duration of Study and Follow-up

Research focusing on short-term symptom changes generally uses a limited, acute time frame. Most studies studies observed responses over defined time intervals ranging from 48 hours up to five days of continuous use. This short follow-up duration is relevant in trials assessing short-term or episodic symptom patterns during the initial, most intense phase of the common cold or flu-like illness.

Due to this focus on acute relief, follow-up durations were limited in most primary research that contributed to the evidence base. There is limited information for long-term outcomes regarding the use of this specific combination. Long-term effects are not fully established, and research does not determine whether any short-term patterns persist or whether there are implications for the overall duration of the illness.

Evidence in Specific Patient Groups and Key Uncertainties

The body of evidence where the combination was evaluated in primarily applies only to the populations studied, which were largely healthy adults between the ages of 18 and 65 experiencing acute cold symptoms. Data for certain groups remain insufficient or absent in the context of controlled trials of this specific formulation, including children under 12, older adults, or individuals with certain pre-existing chronic conditions.

While the available research contributes to the broader evidence landscape, several limitations are noted in the scientific reviews. The exact combination of ingredients has led to some heterogeneity in the findings reported across various systematic reviews of similar combinations. This means comparative evidence is lacking. Additionally, sample sizes were modest in some of the smaller RCTs, and research provides context but not individual predictions regarding how an individual patient will experience the outcomes related to their specific symptoms.

Key Studies & References Over-the-Counter Agents for the Common Cold: Review of Systematic Reviews

Common questions about Fervex (FAQ)

---

Q: What is Fervex indicated for?

A: Fervex contains a combination of active substances. It is indicated for the temporary relief of symptoms associated with colds, flu, and flu-like conditions in adults and adolescents aged 15 years and older. The symptoms Fervex is intended to address typically include headache, fever, runny nose, and sneezing.

---

Q: How does Fervex work to address symptoms?

A: Fervex contains three active ingredients: paracetamol, pheniramine maleate, and ascorbic acid (Vitamin C). The paracetamol component works to help reduce fever and provide temporary relief from mild pain such as headaches. Pheniramine maleate is an antihistamine component that may help reduce symptoms such as watery eyes, sneezing, and runny nose. Ascorbic acid is included as a supplementary vitamin.

---

Q: What are the potential side effects of taking Fervex?

A: The pheniramine maleate component of Fervex is associated with the potential for drowsiness and impaired alertness. These effects may be more pronounced at the start of treatment. Other reported side effects may include symptoms related to the antihistamine component, such as dry mouth or difficulty urinating. Consult a healthcare professional if you experience unexpected or severe effects.

---

Q: Are there any warnings related to using Fervex?

A: Due to the potential for drowsiness caused by pheniramine maleate, individuals should exercise caution when driving or operating machinery. The medicine contains paracetamol; to help prevent overdose, it is essential to check that no other medications being taken also contain paracetamol or other components of Fervex. Consult a healthcare professional if symptoms persist beyond five days or if fever lasts more than three days.

---

Q: Are there any known contraindications for Fervex?

A: Fervex is generally not recommended for individuals under the age of 15 years. It is also generally contraindicated for individuals with certain pre-existing conditions, including severe hepatic insufficiency and a risk of angle-closure glaucoma. It is also not recommended for those with a risk of urinary retention related to urethroprostatic disorders. Patients with specific sensitivities or hereditary disorders (e.g., fructose intolerance, phenylketonuria, or glucose-galactose malabsorption) may have contraindications based on the specific formulation being used.

How to Store and Dispose of Fervex?

Item	Requirement (Official Labeling)
Storage Temperature	Store below 30 C
Environmental Protection	Protect from moisture and light
Packaging	Must remain in the original package
Child Safety	Keep out of the sight and reach of children

Official labeling mandates that Fervex must be stored below 30 C in its original sachet and outer carton to ensure protection from moisture and light. The prepared oral solution must be consumed immediately after reconstitution. To comply with regulatory requirements, the product must be kept out of the sight and reach of children.

Disposal instructions state that expired or unused medicine must not be disposed of via wastewater or household waste and should instead be returned to a pharmacist for appropriate pharmaceutical waste handling, following local regulations.